AGER and familial pancreatic carcinoma: Based on the multiple ways the RAGE pathway has been implicated in the progression of pancreatic cancer and its capacity to modulate radiation response, we evaluated both the anti-tumor activity of the RAGE inhibitor Azeliragon and its potential to enhance radiation response in pancreatic cancer preclinical models.